Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deadline Approaching: Apply for the Fierce AI Innovation Awards
Eli Lilly
Biotech
Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks
Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease for up to $1 billion biobucks.
Will Maddox
Jun 9, 2026 10:16am
Roche sticks with €600M diagnostics investment in Germany
Jun 9, 2026 8:00am
Fierce Pharma
Eli Lilly is the ‘clear winner’ from ADA, RBC analyst says
Jun 8, 2026 3:12pm
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
Fierce Pharma
Lilly, Boehringer slash investment plans in Germany
Jun 3, 2026 3:10pm
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B
Jun 3, 2026 7:00am
Fierce Pharma
